Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

[A Case of FOLFOXIRI plus BV Therapy Responding to Liver Metastasis of Rectal Cancer with the Portal Venous Tumor Thrombi(Vp4)as Oncologic Emergency].

Nakamura M, Ishigure K, Watanabe T, Mashita N, Tobinaga J, Fukuyama R.

Gan To Kagaku Ryoho. 2019 Nov;46(11):1791-1793. Japanese.

PMID:
31748495
2.

Efficient Generation of Cynomolgus Monkey Induced Pluripotent Stem Cell-Derived Intestinal Organoids with Pharmacokinetic Functions.

Onozato D, Yamashita M, Fukuyama R, Akagawa T, Kida Y, Koeda A, Hashita T, Iwao T, Matsunaga T.

Stem Cells Dev. 2018 Aug 1;27(15):1033-1045. doi: 10.1089/scd.2017.0216. Epub 2018 Jun 29.

PMID:
29742964
3.

An acute bout of housework activities has beneficial effects on executive function.

Tsuchiya K, Mitsui S, Fukuyama R, Yamaya N, Fujita T, Shimoda K, Tozato F.

Neuropsychiatr Dis Treat. 2017 Dec 22;14:61-72. doi: 10.2147/NDT.S153813. eCollection 2018.

4.

Surgical Treatment of Rotational Vertebral Artery Syndrome Induced by Spinal Tumor: A Case Report and Literature Review.

Haimoto S, Nishimura Y, Hara M, Yamamoto Y, Fukuoka T, Fukuyama R, Wakabayashi T, Ginsberg HJ.

NMC Case Rep J. 2017 Sep 7;4(4):101-105. doi: 10.2176/nmccrj.cr.2016-0152. eCollection 2017 Oct.

5.

Coordination Nanosheets Based on Terpyridine-Zinc(II) Complexes: As Photoactive Host Materials.

Tsukamoto T, Takada K, Sakamoto R, Matsuoka R, Toyoda R, Maeda H, Yagi T, Nishikawa M, Shinjo N, Amano S, Iokawa T, Ishibashi N, Oi T, Kanayama K, Kinugawa R, Koda Y, Komura T, Nakajima S, Fukuyama R, Fuse N, Mizui M, Miyasaki M, Yamashita Y, Yamada K, Zhang W, Han R, Liu W, Tsubomura T, Nishihara H.

J Am Chem Soc. 2017 Apr 19;139(15):5359-5366. doi: 10.1021/jacs.6b12810. Epub 2017 Apr 4.

PMID:
28320204
6.

[Intraoperative Artery Wall Stimulating Electromyography during Microvascular Decompression Surgery to Treat Hemifacial Spasm:A Case Report].

Yamashita R, Nakamura T, Fukuyama R, Ishikawa K, Hayashi T, Miyazaki R, Ohtake M, Sato M, Tateishi K, Shimizu N, Suenaga J, Murata H.

No Shinkei Geka. 2017 Mar;45(3):247-251. doi: 10.11477/mf.1436203487. Japanese.

PMID:
28297691
7.

Epstein-Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis.

Satou A, Kohno A, Fukuyama R, Elsayed AA, Nakamura S.

Hum Pathol. 2017 Jan;59:147-151. doi: 10.1016/j.humpath.2016.08.001. Epub 2016 Aug 26.

PMID:
27569297
8.

Kinetics of versican-expressing macrophages in bone marrow after cord blood stem cell transplantation for treatment of acute myelogenous leukaemia.

Senda M, Fukuyama R, Nagasaka T.

J Clin Pathol. 2016 Oct;69(10):906-11. doi: 10.1136/jclinpath-2015-203496. Epub 2016 Mar 7.

9.

Overexpression of BCLXL in Osteoblasts Inhibits Osteoblast Apoptosis and Increases Bone Volume and Strength.

Moriishi T, Fukuyama R, Miyazaki T, Furuichi T, Ito M, Komori T.

J Bone Miner Res. 2016 Jul;31(7):1366-80. doi: 10.1002/jbmr.2808. Epub 2016 Mar 4.

10.

Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome.

Tatekawa S, Umemura K, Fukuyama R, Kohno A, Taniwaki M, Kuroda J, Morishita Y.

Clin Case Rep. 2015 Jun;3(6):472-8. doi: 10.1002/ccr3.284. Epub 2015 Apr 22.

11.

Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.

Tanahashi K, Natsume A, Ohka F, Motomura K, Alim A, Tanaka I, Senga T, Harada I, Fukuyama R, Sumiyoshi N, Sekido Y, Wakabayashi T.

J Neuropathol Exp Neurol. 2015 Jul;74(7):704-9. doi: 10.1097/NEN.0000000000000211.

PMID:
26049897
12.

Blockade of gap junction hemichannel protects secondary spinal cord injury from activated microglia-mediated glutamate exitoneurotoxicity.

Umebayashi D, Natsume A, Takeuchi H, Hara M, Nishimura Y, Fukuyama R, Sumiyoshi N, Wakabayashi T.

J Neurotrauma. 2014 Dec 15;31(24):1967-74. doi: 10.1089/neu.2013.3223. Epub 2014 Sep 23.

13.

Relapse of acute myeloid leukemia mimicking autoimmune pancreatitis after bone marrow transplantation.

Ozeki K, Morishita Y, Sakai D, Nakamura Y, Fukuyama R, Umemura K, Yamaguchi Y, Tatekawa S, Watamoto K, Ozeki K, Kohno A.

Intern Med. 2014;53(3):247-51.

14.

[On the correlation between histological and cytological diagnosis, and the intrinsic 5 subtypes].

Sumiyoshi N, Fukuyama R, Senda M, Yokoi T, Nagasaka T.

Rinsho Byori. 2013 Oct;61(10):887-92. Japanese.

PMID:
24371992
15.

Spinal intradural cystic venous angioma originating from a nerve root in the cauda equina.

Nishimura Y, Hara M, Natsume A, Nakajima Y, Fukuyama R, Wakabayashi T, Ginsberg HJ.

J Neurosurg Spine. 2013 Dec;19(6):716-20. doi: 10.3171/2013.8.SPINE121012. Epub 2013 Oct 4.

PMID:
24093468
16.

Lymphohistiocytic and small cell pattern of anaplastic large cell lymphoma, ALK positive, arising in an 86-year-old woman.

Satou A, Asano N, Tatekawa S, Fukuyama R, Nakamura S.

Pathol Int. 2013 Apr;63(4):230-2. doi: 10.1111/pin.12047. No abstract available.

PMID:
23692425
17.

Interferon-β delivery via human neural stem cell abates glial scar formation in spinal cord injury.

Nishimura Y, Natsume A, Ito M, Hara M, Motomura K, Fukuyama R, Sumiyoshi N, Aoki I, Saga T, Lee HJ, Wakabayashi T, Kim SU.

Cell Transplant. 2013;22(12):2187-201. doi: 10.3727/096368912X657882. Epub 2012 Oct 12.

PMID:
23068051
18.

Intra-extradural dumbbell-shaped hemangioblastoma manifesting as subarachnoid hemorrhage in the cauda equina.

Nishimura Y, Hara M, Natsume A, Takemoto M, Fukuyama R, Wakabayashi T.

Neurol Med Chir (Tokyo). 2012;52(9):659-65. Review.

19.

Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.

Moriishi T, Fukuyama R, Ito M, Miyazaki T, Maeno T, Kawai Y, Komori H, Komori T.

PLoS One. 2012;7(6):e40143. doi: 10.1371/journal.pone.0040143. Epub 2012 Jun 29.

20.

SP7 inhibits osteoblast differentiation at a late stage in mice.

Yoshida CA, Komori H, Maruyama Z, Miyazaki T, Kawasaki K, Furuichi T, Fukuyama R, Mori M, Yamana K, Nakamura K, Liu W, Toyosawa S, Moriishi T, Kawaguchi H, Takada K, Komori T.

PLoS One. 2012;7(3):e32364. doi: 10.1371/journal.pone.0032364. Epub 2012 Mar 2.

21.

Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis.

Moriishi T, Maruyama Z, Fukuyama R, Ito M, Miyazaki T, Kitaura H, Ohnishi H, Furuichi T, Kawai Y, Masuyama R, Komori H, Takada K, Kawaguchi H, Komori T.

PLoS One. 2011;6(11):e27487. doi: 10.1371/journal.pone.0027487. Epub 2011 Nov 17.

22.

Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats.

Fujita M, Ohnishi K, Takaoka S, Ogasawara K, Fukuyama R, Nakamuta H.

Biol Pharm Bull. 2011;34(11):1696-701.

23.

Pyruvate dehydrogenase kinase 4 induces bone loss at unloading by promoting osteoclastogenesis.

Wang Y, Liu W, Masuyama R, Fukuyama R, Ito M, Zhang Q, Komori H, Murakami T, Moriishi T, Miyazaki T, Kitazawa R, Yoshida CA, Kawai Y, Izumi S, Komori T.

Bone. 2012 Jan;50(1):409-19. doi: 10.1016/j.bone.2011.07.012. Epub 2011 Jul 23.

PMID:
21803180
24.

Dosing time-dependency of the arthritis-inhibiting effect of tacrolimus in mice.

Obayashi K, Tomonari M, Yoshimatsu H, Fukuyama R, Ieiri I, Higuchi S, To H.

J Pharmacol Sci. 2011;116(3):264-73. Epub 2011 Jun 18.

25.

Anti-osteoporosis effect of 5-bromo-2-(4-chlorobenzoyl)-(Z)-3-(2-cyano-3-hydroxybut-2-enonyl)aminobenzo[b]furan: a novel selective estrogen receptor modulator.

Fukuyama R, Shimokawa A, Kodama Y, Fujita M, Ohishi Y, Ando Y, Koida M, Nakamuta H.

J Pharmacol Sci. 2011;116(2):214-20. Epub 2011 May 21.

26.

Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.

Matsushima M, Horinaga M, Fukuyama R, Yanaihara H, Kikuchi E, Kawachi M, Iida M, Nakahira Y, Oya M, Asakura H.

Oncol Lett. 2011 Jan;2(1):13-19. Epub 2010 Nov 23.

27.

Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.

Horinaga M, Fukuyama R, Iida M, Yanaihara H, Nakahira Y, Nonaka S, Deguchi N, Asakura H.

Urology. 2010 Nov;76(5):1267.e1-6. doi: 10.1016/j.urology.2010.03.028.

PMID:
21056277
28.

Tumor thickness, depth of invasion, and Bcl-2 expression are correlated with FDG-uptake in oral squamous cell carcinomas.

Suzuki H, Fukuyama R, Hasegawa Y, Tamaki T, Nishio M, Nakashima T, Tatematsu M.

Oral Oncol. 2009 Oct;45(10):891-7. doi: 10.1016/j.oraloncology.2009.03.009. Epub 2009 May 19.

PMID:
19457711
29.

Preparation of novel (Z)-4-ylidenebenzo[b]furo[3,2-d][1,3]oxazines and their biological activity.

Tabuchi Y, Ando Y, Kanemura H, Kawasaki I, Ohishi T, Koida M, Fukuyama R, Nakamuta H, Ohta S, Nishide K, Ohishi Y.

Bioorg Med Chem. 2009 Jun 1;17(11):3959-67. doi: 10.1016/j.bmc.2009.04.017. Epub 2009 Apr 12.

PMID:
19406645
30.

BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter.

Cicek M, Fukuyama R, Cicek MS, Sizemore S, Welch DR, Sizemore N, Casey G.

Clin Exp Metastasis. 2009;26(3):229-37. doi: 10.1007/s10585-009-9235-1. Epub 2009 Jan 23.

31.

Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription.

Fukuyama R, Niculaita R, Ng KP, Obusez E, Sanchez J, Kalady M, Aung PP, Casey G, Sizemore N.

Oncogene. 2008 Oct 9;27(46):6044-55. doi: 10.1038/onc.2008.204. Epub 2008 Jun 30.

32.

Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency.

Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, Fukuyama R, Miyazaki T, Kitaura H, Nakamura K, Fujita T, Kanatani N, Moriishi T, Yamana K, Liu W, Kawaguchi H, Nakamura K, Komori T.

Dev Dyn. 2007 Jul;236(7):1876-90.

33.

Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells.

Fukuyama R, Ng KP, Cicek M, Kelleher C, Niculaita R, Casey G, Sizemore N.

Mol Carcinog. 2007 May;46(5):402-13.

PMID:
17186550
34.

A novel oxazine ring closure reaction affording (Z)-((E)-2-styrylbenzo[b]furo[3,2-d][1,3]oxazin-4-ylideno)acetaldehydes and their anti-osteoclastic bone resorption activity.

Ando Y, Ando K, Yamaguchi M, Kunitomo J, Koida M, Fukuyama R, Nakamuta H, Yamashita M, Ohta S, Ohishi Y.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5849-54. Epub 2006 Sep 1.

PMID:
16945531
35.

Cbf beta regulates Runx2 function isoform-dependently in postnatal bone development.

Kanatani N, Fujita T, Fukuyama R, Liu W, Yoshida CA, Moriishi T, Yamana K, Miyazaki T, Toyosawa S, Komori T.

Dev Biol. 2006 Aug 1;296(1):48-61. Epub 2006 Apr 4.

36.

Novel enhanced lung-colonizing variant of murine MBT-2 bladder cancer cells.

Horinaga M, Fukuyama R, Nishiyama T, Harsch KM, Cicek M, Heston W, Sizemore N, Casey G, Larchian W.

Urology. 2005 Sep;66(3):676-81.

PMID:
16140114
37.

Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.

Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W.

Urology. 2005 Aug;66(2):461-6.

PMID:
16040105
38.

Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.

Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G.

Cancer Res. 2005 May 1;65(9):3586-95.

39.

Dexamethasone inhibits insulin-induced chondrogenesis of ATDC5 cells by preventing PI3K-Akt signaling and DNA binding of Runx2.

Fujita T, Fukuyama R, Enomoto H, Komori T.

J Cell Biochem. 2004 Oct 1;93(2):374-83.

PMID:
15368363
40.

Osteoporosis requires bone-specific statins.

Koida M, Fukuyama R, Nakamuta H.

Curr Pharm Des. 2004;10(21):2605-13. Review.

PMID:
15320748
41.

Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling.

Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K, Komori T.

J Cell Biol. 2004 Jul 5;166(1):85-95. Epub 2004 Jun 28.

42.

Statins inhibit osteoblast migration by inhibiting Rac-Akt signaling.

Fukuyama R, Fujita T, Azuma Y, Hirano A, Nakamuta H, Koida M, Komori T.

Biochem Biophys Res Commun. 2004 Mar 12;315(3):636-42.

PMID:
14975748
43.

Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.

Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K, Komori T.

J Biol Chem. 2003 Jun 27;278(26):23971-7. Epub 2003 Apr 15.

44.

Muramyl dipeptide injected into crushed sciatic nerve, activates macrophages and promotes recovery of walking locomotion in rats.

Fukuyama R, Takeda H, Fushiki S, Yamamoto T.

Restor Neurol Neurosci. 1998;13(3-4):213-9.

PMID:
12671282
45.

Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure.

Harada S, Nakata T, Oguni A, Kido H, Hatta T, Fukuyama R, Fushiki S, Sasaki S, Takeda K.

Hypertens Res. 2002 Sep;25(5):779-86.

46.

Core-binding factor beta interacts with Runx2 and is required for skeletal development.

Yoshida CA, Furuichi T, Fujita T, Fukuyama R, Kanatani N, Kobayashi S, Satake M, Takada K, Komori T.

Nat Genet. 2002 Dec;32(4):633-8. Epub 2002 Nov 18.

PMID:
12434152
47.

A newly established neuronal rho-0 cell line highly susceptible to oxidative stress accumulates iron and other metals. Relevance to the origin of metal ion deposits in brains with neurodegenerative disorders.

Fukuyama R, Nakayama A, Nakase T, Toba H, Mukainaka T, Sakaguchi H, Saiwaki T, Sakurai H, Wada M, Fushiki S.

J Biol Chem. 2002 Nov 1;277(44):41455-62. Epub 2002 Aug 22.

48.
49.

A Japanese patient with cerebrotendinous xanthomatosis has different mutations within two functional domains of CYP27.

Toba H, Fukuyama R, Sasaki M, Shiga K, Ishibashi S, Fushiki S.

Clin Genet. 2002 Jan;61(1):77-8. No abstract available.

PMID:
11903362
50.

Transactivation of core binding factor alpha1 as a basic mechanism to trigger parathyroid hormone-induced osteogenesis.

Fujita T, Fukuyama R, Izumo N, Hirai T, Meguro T, Nakamuta H, Koida M.

Jpn J Pharmacol. 2001 Aug;86(4):405-16.

Supplemental Content

Loading ...
Support Center